Comparing a new blood transfusion system to standard care
Part of Blood & lymphatic, Cancer clinical trials.
This study compares a new blood transfusion system (Hemanext ONE®) to standard red blood cell transfusions for people with blood cancers like MDS who need regular transfusions. The goal is to see if it improves how patients feel or reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a blood cancer, like MDS or leukemia, that needs regular red blood cell transfusions
- You have needed at least 2 units of red blood cells every 8 weeks for the last 16 weeks
- You are not pregnant or planning to become pregnant in the next 14 months
- You do not have severe heart, lung, or kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of red blood cell transfusion that holds less oxygen. It may help people with sickle cell anemia who already get regular transfusions.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
This study looks at how well transfusions work and how they affect quality of life in people with lower-risk MDS who need regular blood transfusions. The goal is to find what predicts a good transfusion response and to improve care.
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.